No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
INCY240719P60000
- 0.01
- -0.04-80.00%
15min DelayClose Jul 19 15:50 ET
0.05High0.01Low
0.03Open0.05Pre Close3 Volume40 Open Interest60.00Strike Price9.00Turnover399.67%IV8.93%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier0DDays to Expiry0.01Extrinsic Value100Contract SizeAmericanOptions Type-0.0107Delta0.0105Gamma6587.00Leverage Ratio-0.8919Theta0.0000Rho-70.61Eff Leverage0.0002Vega
Intraday
- 5D
- Daily
News
Vitiligo Therapeutic Assessment Analysis Report 2024: Comprehensive Insights About 20+ Companies and 20+ Pipeline Drugs Featuring Key Players - AbbVie, Pfizer, Incyte, Ahammune Biosciences, & Amgen
Most Shorted S&P 500 Stocks in June
Is Incyte Corporation's (NASDAQ:INCY) Recent Stock Performance Tethered To Its Strong Fundamentals?
Incyte, Moderna Among Most Shorted S&P 500 Healthcare Stocks in June
Is Incyte Corporation's (NASDAQ:INCY) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Incyte (NASDAQ:INCY) has had a great run on the share market with its stock up by a significant 21% over the last three months. Given that the market rewards strong financials in the long-term, we
Goldman Sachs Adjusts Price Target on Incyte to $61 From $60, Maintains Neutral Rating
Incyte (INCY) has an average outperform rating and a price target range of $48 to $88, according to analysts polled by Capital IQ.
Comments
Morning Movers
Gapping up
$Paramount Global-B(PARA.US$ 's stock increased by 3.85% following a report from the New York Times that billionaire Barry Diller is considering a takeover bid for the company after the studio he used to lead withdrew from a merger with Skydance Media.
$PayPal(PYPL.US$ shares rose by 1.39% after Susquehanna raised its rating from Neutral to Positive.
Gapping down
$Tesla(TSLA.US$ 's stock declined ...
Gapping up
$Paramount Global-B(PARA.US$ 's stock increased by 3.85% following a report from the New York Times that billionaire Barry Diller is considering a takeover bid for the company after the studio he used to lead withdrew from a merger with Skydance Media.
$PayPal(PYPL.US$ shares rose by 1.39% after Susquehanna raised its rating from Neutral to Positive.
Gapping down
$Tesla(TSLA.US$ 's stock declined ...
30
2
I am currently a full-time NSF, and I have been investing in about 6-7 months.
I managed to garner an average of 3% a month the past 4 months using several methods of trading.
I started trading about 6 months ago with a small sum to test the waters until I was fully ready to begin my journey in March.
Trading is relatively simple if you just try to minimize your risk as much as possible and just throw that gambler's mindset into the bin...
I managed to garner an average of 3% a month the past 4 months using several methods of trading.
I started trading about 6 months ago with a small sum to test the waters until I was fully ready to begin my journey in March.
Trading is relatively simple if you just try to minimize your risk as much as possible and just throw that gambler's mindset into the bin...
+4
212
75
This month was a really chaotic month for me as it was very volatile with huge ups and downs.
My three biggest winners this month were INCY, APPL, and NVDA. Although my P/L could be higher if I did not sell my NVDA early, I still managed to reap the 5% gain in NVDA.
I believe NVDA holds massive growth potential as many companies have started shifting to NVDA, and AI hype will not seem to die down so soon. I will be expecting around 30 billion in revenue next quarter, which led me to buy ...
My three biggest winners this month were INCY, APPL, and NVDA. Although my P/L could be higher if I did not sell my NVDA early, I still managed to reap the 5% gain in NVDA.
I believe NVDA holds massive growth potential as many companies have started shifting to NVDA, and AI hype will not seem to die down so soon. I will be expecting around 30 billion in revenue next quarter, which led me to buy ...
11
5
This month was a really chaotic month for me as it was very volatile with huge ups and downs.
My three biggest winners this month were INCY, APPL, and NVDA. Although my P/L could be higher if I did not sell my NVDA early, I still managed to reap the 5% gain in NVDA.
I believe NVDA holds massive growth potential as many companies have started shifting to NVDA, and AI hype will not seem to die down so soon. I will be expecting around 30 billion in revenue next quarter, which led ...
My three biggest winners this month were INCY, APPL, and NVDA. Although my P/L could be higher if I did not sell my NVDA early, I still managed to reap the 5% gain in NVDA.
I believe NVDA holds massive growth potential as many companies have started shifting to NVDA, and AI hype will not seem to die down so soon. I will be expecting around 30 billion in revenue next quarter, which led ...
8
» Holdings: 87
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte(INCY.US$
$BeiGene(BGNE.US$
$ACADIA Pharmaceuticals(ACAD.US$
$Madrigal Pharmaceuticals(MDGL.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Revolution Medicines(RVMD.US$
$Kymera Therapeutics(KYMR.US$
$AbCellera Biologics(ABCL.US$
$Bicycle Therapeutics(BCYC.US$
$Edgewise Therapeutics(EWTX.US$
$Immunocore(IMCR.US$
$Kodiak Sciences(KOD.US$
$Roivant Sciences(ROIV.US$
...
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte(INCY.US$
$BeiGene(BGNE.US$
$ACADIA Pharmaceuticals(ACAD.US$
$Madrigal Pharmaceuticals(MDGL.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Revolution Medicines(RVMD.US$
$Kymera Therapeutics(KYMR.US$
$AbCellera Biologics(ABCL.US$
$Bicycle Therapeutics(BCYC.US$
$Edgewise Therapeutics(EWTX.US$
$Immunocore(IMCR.US$
$Kodiak Sciences(KOD.US$
$Roivant Sciences(ROIV.US$
...
8
Read more
Ivo Stoyanov : ..
raz1 : how do iset my chart to see gaps